Peptídeos

A synthetic peptide for use as a blocking control in assays to test for specificity of C10orf96 antibody, catalog no. 70R-3327

A synthetic peptide for use as a blocking control in assays to test for specificity of Sec31a antibody, catalog no. 70R-9307

Universal Major Histocompatibility Complex (MHC) H2 I-Ab epitope for CD4+ T-cell recruitment and activation
SB-PEPTIDE offers I-Ab restricted PADRE peptide ak(Cha)VAAWTLKAAa-Ahx-C.
Pan DR-binding epitope (PADRE) is a universal synthetic peptide binding Major Histocompatibility Complex (MHC)-II receptors, of which H2 complex (mouse MHC), present on specific immune cells. 4 class II loci exist in the region I of the H2 complex gene (see image below), known as Aa & Ea loci (α encoded) and Ab & Eb loci (β encoded), that are similar to the DR, DP and DQ loci of the Human Leukocyte Antigen (HLA) complex.
I-Ab restricted PADRE peptide interacts specifically with mouse H2-I-Ab receptors that activate antigen specific CD4+ T-cells in the same way as PADRE peptide’s interaction with HLA-DR receptors. This feature places I-Ab restricted PADRE as promising adjuvant for immunotherapeutic vaccines against chronicle diseases such as infections, Alzheimer or cancer. Similarly to the original PADRE peptide, the restricted version also acts as a Toll-like receptor (TLR) agonist and was described as alternative carrier, such as KLH/BSA or OVA, for prophylaxis and therapeutic vaccines. An aminocaproic acid (Ahx) linker, attached to an additional C-terminal Cysteine, was added to the sequence to allow both the peptide and its loading to interact independently and freely with molecules exposed to them. This modification is used for the loading of antigenic determinants in solution in order to enhance the immune response against a specific antigen (AG).

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC25A14 antibody, catalog no. 70R-1750

A synthetic peptide for use as a blocking control in assays to test for specificity of ASPH antibody, catalog no. 70R-7074

A synthetic peptide for use as a blocking control in assays to test for specificity of C19orf47 antibody, catalog no. 70R-3346

A synthetic peptide for use as a blocking control in assays to test for specificity of IER5 antibody, catalog no. 70R-2561

A synthetic peptide for use as a blocking control in assays to test for specificity of DCDC2 antibody, catalog no. 70R-4501

A synthetic peptide for use as a blocking control in assays to test for specificity of PPP2R5E antibody, catalog no. 70R-9425

A synthetic peptide for use as a blocking control in assays to test for specificity of DIRAS1 antibody, catalog no. 70R-5821

A synthetic peptide for use as a blocking control in assays to test for specificity of PIWIL1 antibody, catalog no. 70R-3108

A synthetic peptide for use as a blocking control in assays to test for specificity of MTPN antibody, catalog no. 70R-2590

A synthetic peptide for use as a blocking control in assays to test for specificity of WDR54 antibody, catalog no. 70R-10100

A synthetic peptide for use as a blocking control in assays to test for specificity of TRDMT1 antibody, catalog no. 70R-2240

A synthetic peptide for use as a blocking control in assays to test for specificity of PPP2R5A antibody, catalog no. 70R-2950

Vasotocin is a peptide hormone that is found in the hypothalamus. It is an activator of the vasopressin receptor and has been shown to activate ion channels and inhibit the release of neurotransmitters. Vasotocin also binds to a specific receptor on the surface of cells, which may be involved in cell biology and may have applications in pharmacology and antibody research. Vasotocin is purified from pig pituitary glands.

A synthetic peptide for use as a blocking control in assays to test for specificity of ZFP90 antibody, catalog no. 70R-7874

A synthetic peptide for use as a blocking control in assays to test for specificity of SEMA4F antibody, catalog no. 70R-6853

m-dPEG®24-Lipoamide is a PEG molecule conjugated with a lipid moiety. m-dPEG®24-Lipoamide, conjugated to this lipid constituent, is very important especially in drug delivery and vaccine development as it helps improve the stability and circulation time of lipid nanoparticles (LNPs) and liposomes.

A synthetic peptide for use as a blocking control in assays to test for specificity of CASP4 antibody, catalog no. 70R-9650

A synthetic peptide for use as a blocking control in assays to test for specificity of UBE2O antibody, catalog no. 70R-3984

A synthetic peptide for use as a blocking control in assays to test for specificity of TLE4 antibody, catalog no. 70R-7916

A synthetic peptide for use as a blocking control in assays to test for specificity of PARP6 antibody, catalog no. 70R-2153

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF491 antibody, catalog no. 70R-8126

A synthetic peptide for use as a blocking control in assays to test for specificity of FANCE antibody, catalog no. 70R-2296

A synthetic peptide for use as a blocking control in assays to test for specificity of CLPB antibody, catalog no. 70R-3956

A synthetic peptide for use as a blocking control in assays to test for specificity of HBP1 antibody, catalog no. 70R-8294

A synthetic peptide for use as a blocking control in assays to test for specificity of Sult1c2 antibody, catalog no. 70R-8805

A synthetic peptide for use as a blocking control in assays to test for specificity of MBNL1 antibody, catalog no. 70R-1551

A synthetic peptide for use as a blocking control in assays to test for specificity of IFIH1 antibody, catalog no. 70R-4787

A synthetic peptide for use as a blocking control in assays to test for specificity of TARS antibody, catalog no. 70R-1227

A synthetic peptide for use as a blocking control in assays to test for specificity of SCGB1A1 antibody, catalog no. 70R-5399

MAGE-A3 (195-203) peptide – IMPKAGLLI – Epitope of Melanoma Antigen Gene A3

A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf127 antibody, catalog no. 70R-1830

A synthetic peptide for use as a blocking control in assays to test for specificity of DNAJC10 antibody, catalog no. 70R-6576

A synthetic peptide for use as a blocking control in assays to test for specificity of DYSFIP1 antibody, catalog no. 70R-4114

A synthetic peptide for use as a blocking control in assays to test for specificity of RPL3 antibody, catalog no. 70R-4713

A synthetic peptide for use as a blocking control in assays to test for specificity of SIRPA antibody, catalog no. 70R-10426

A synthetic peptide for use as a blocking control in assays to test for specificity of CA8 antibody, catalog no. 70R-1122

A synthetic peptide for use as a blocking control in assays to test for specificity of SNRPA antibody, catalog no. 70R-4992

A synthetic peptide for use as a blocking control in assays to test for specificity of LIN7C antibody, catalog no. 70R-2196

A synthetic peptide for use as a blocking control in assays to test for specificity of COPS4 antibody, catalog no. 70R-3609

Biotin-SARS-CoV-2 Spike RBD 371-394 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 371-394 peptide. SARS-CoV-2 Spike RBD 371-394 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 371-394 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBD:
The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

Boc-Leu-Lys-Arg-AMC is an inhibitor of the human erythrocyte receptor for thrombin. It has shown activity in a number of other protein interactions, such as with the human receptor for epidermal growth factor (EGF) and the human receptor for insulin-like growth factor II. Boc-Leu-Lys-Arg-AMC is used as a research tool to study the function of proteins, including ion channels and receptors. This compound is also used as an antibody in immunological studies that examine protein interactions. Boc-Leu-Lys-Arg-AMC can be purchased in high purity and at a reasonable price from our store.

Voltage-gated sodium channels blocker

A synthetic peptide for use as a blocking control in assays to test for specificity of TSPAN17 antibody, catalog no. 70R-6680

CGRP (Human, 8-37) is a peptide derived from the calcitonin gene-related peptide (CGRP) that is found in the nervous system and other tissues in humans. It is a truncated form of the full-length CGRP peptide, consisting of the last 30 amino acids of the CGRP sequence (amino acids 8-37).
CGRP is a potent vasodilator and plays a key role in regulating blood flow and blood pressure. It is also involved in pain perception, inflammation, and neurogenic inflammation. CGRP (Human, 8-37) is an antagonist of CGRP, meaning that it binds to the CGRP receptor without activating it, thereby blocking the effects of CGRP.
CGRP (Human, 8-37) has been used as a research tool to study the physiological and pathological roles of CGRP in various tissues and diseases, such as migraine headaches, cardiovascular diseases, and inflammatory disorders. It has also been investigated as a potential therapeutic agent for these conditions, as well as for the treatment of pain and other neurological disorders.
This product is available as a 0.5mg vial.

NHS-dPEG®12 Biotin is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. NHS-dPEG®12 Biotin is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic peptide for use as a blocking control in assays to test for specificity of MAP3K7IP1 antibody, catalog no. 70R-5775

A synthetic peptide for use as a blocking control in assays to test for specificity of USP1 antibody, catalog no. 70R-9732

A synthetic peptide for use as a blocking control in assays to test for specificity of Rad21 antibody, catalog no. 70R-9430

A synthetic peptide for use as a blocking control in assays to test for specificity of PSEN1 antibody, catalog no. 70R-6264

A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf153 antibody, catalog no. 70R-3503

A synthetic peptide for use as a blocking control in assays to test for specificity of RPL27 antibody, catalog no. 70R-2387

A synthetic peptide for use as a blocking control in assays to test for specificity of GGCX antibody, catalog no. 70R-6289

A synthetic peptide for use as a blocking control in assays to test for specificity of EIF3EIP antibody, catalog no. 70R-4419

Galanin is a peptide that belongs to the family of neuropeptides and is found in the endocrine system, the central and peripheral nervous systems. It has been shown to inhibit the release of acetylcholine in the central nervous system and interestingly in Alzheimer’s disease patients, hyperinervation of galanin fibres has been found. Galanin is also known to have a variety of physiological effects including inhibition of insulin release, stimulation of prolactin and growth hormone secretion and it also plays a role in feeding, mood, cognition, neuroendocrine regulation and affects gastrointestinal motility. Galanin asserts its effects through associated with G-protein coupled receptors. This product is available as a 0.5mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNK10 antibody, catalog no. 70R-1532

A synthetic peptide for use as a blocking control in assays to test for specificity of RASL12 antibody, catalog no. 70R-5822

A synthetic peptide for use as a blocking control in assays to test for specificity of PSG6 antibody, catalog no. 70R-3426

A synthetic peptide for use as a blocking control in assays to test for specificity of TRIM34 antibody, catalog no. 70R-8362

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF488 antibody, catalog no. 70R-8146

A synthetic peptide for use as a blocking control in assays to test for specificity of AGBL5 antibody, catalog no. 70R-3580

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNN2 antibody, catalog no. 70R-1495

A synthetic peptide for use as a blocking control in assays to test for specificity of FBXO4 antibody, catalog no. 70R-2792

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP3A4 antibody, catalog no. 70R-7491

A synthetic peptide for use as a blocking control in assays to test for specificity of MICA antibody, catalog no. 70R-1705

A synthetic peptide for use as a blocking control in assays to test for specificity of 2810405K02Rik antibody, catalog no. 70R-9211

A synthetic peptide for use as a blocking control in assays to test for specificity of ATG2A antibody, catalog no. 70R-3823

A synthetic peptide for use as a blocking control in assays to test for specificity of GNL3L antibody, catalog no. 70R-3043

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM118A antibody, catalog no. 70R-4554

A synthetic peptide for use as a blocking control in assays to test for specificity of PCBP3 antibody, catalog no. 70R-4780

FK-506 is an immunosuppressant that is produced by fermentation. It is used to prevent the rejection of transplanted organs and to treat a number of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. FK-506 binds to the IL-2 receptor on T-cells and inhibits their proliferation, thereby preventing activation of other immune cells. FK-506 has been shown to be effective in treating a number of diseases, including myocardial infarcts, coronary heart disease, and oral hypoglycaemic. The optimum concentration for this drug is not known, but it appears that higher concentrations are more beneficial in treating some conditions.

SPDP-dPEG®12-Acid is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. SPDP-dPEG®12-Acid is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic peptide for use as a blocking control in assays to test for specificity of LSM6 antibody, catalog no. 70R-4774

A synthetic peptide for use as a blocking control in assays to test for specificity of ODF4 antibody, catalog no. 70R-6941

A synthetic peptide for use as a blocking control in assays to test for specificity of RP2 antibody, catalog no. 70R-4335

Biotin-SARS-CoV-2 Spike RBD 319-335 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 319-335 peptide. SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studies
SARS-CoV-2 Spike (S) glycoprotein
Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.
With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane.
SARS-CoV-2 Spike RBD:
The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry.

A synthetic peptide for use as a blocking control in assays to test for specificity of NUBP1 antibody, catalog no. 70R-4539

A synthetic peptide for use as a blocking control in assays to test for specificity of IER5L antibody, catalog no. 70R-4284

A synthetic peptide for use as a blocking control in assays to test for specificity of MATN3 antibody, catalog no. 70R-5334

A synthetic peptide for use as a blocking control in assays to test for specificity of HSPA1A antibody, catalog no. 70R-1244

A synthetic peptide for use as a blocking control in assays to test for specificity of MRPL48 antibody, catalog no. 70R-2434

A synthetic peptide for use as a blocking control in assays to test for specificity of PLAC9 antibody, catalog no. 70R-3519

A synthetic peptide for use as a blocking control in assays to test for specificity of PLP2 antibody, catalog no. 70R-1891

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP11B2 antibody, catalog no. 70R-3457

A synthetic peptide for use as a blocking control in assays to test for specificity of PAFAH1B2 antibody, catalog no. 70R-3207

Endothelin-2 (ET-2) and Endothelin-1 (ET-1) differ from each other by 2 amino acids and have affinity for ETA and ETB G-protein coupled receptors which are found in a variety of tissues, including lungs, heart, kidneys, uterus and vasculature. It is believed that ET-2 is a potent vasoconstrictor and may play a role in cancer, immunology and heart failure.
This product has disulfide bonds between Cys1-Cys and Cys3-Cys11, is of Canine source and is available as a 0.1mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of COBLL1 antibody, catalog no. 70R-3863

A synthetic peptide for use as a blocking control in assays to test for specificity of HDDC3 antibody, catalog no. 70R-4274

CCK-33 is a peptide that was originally isolated from porcine brain. It has been shown to be an activator of ion channels, a ligand for receptors, and an inhibitor of protein interactions. CCK-33 is also a pharmacological tool that can be used to study the role of ion channels in cellular processes such as neurotransmission and cell proliferation. CCK-33 is a receptor antagonist, which means it binds to the receptor and blocks the binding site. This prevents other compounds from binding to the receptor and activating it, thereby blocking its effects.

A synthetic peptide for use as a blocking control in assays to test for specificity of C20orf141 antibody, catalog no. 70R-3827

A synthetic peptide for use as a blocking control in assays to test for specificity of RPL8 antibody, catalog no. 70R-1429

Obestatin is a peptide that was originally isolated from rat and mouse brain. It is a potent inhibitor of Kv1.3 and Kv1.5 potassium channels, with an IC50 of about 1 nM for both channels, but has no effect on other ion channels. Obestatin also inhibits the binding of antibodies to epitopes on the surface of cells, which may be due to its ability to inhibit cell-cell adhesion. The antibody-binding activity of obestatin is also inhibited by peptides corresponding to residues in the N-terminal region of obestatin, but not by peptides corresponding to residues in the C-terminal region. Obestatin has been shown to activate receptor tyrosine kinase (RTK) pathways and induce signaling cascades that lead to the proliferation and differentiation of tumor cells.

A synthetic peptide for use as a blocking control in assays to test for specificity of CD160 antibody, catalog no. 70R-5801